Latest / Breaking News To Trading Moves
Ultragenyx Setrusumab Miss: Fracture Endpoint Failure
Ultragenyx Plunges After Setrusumab Miss: When “Better BMD” Doesn’t Mean Fewer Fractures
A rare-disease biotech just got cut in half after a Phase 3 miss. Ultragenyx’s setrusumab improved bone density, but didn’t deliver what investors really needed: fewer fractures.
What Happened
Ultragenyx ($RARE) said its late-stage studies of setrusumab (UX143) in osteogenesis imperfecta (brittle-bone disease) failed to meet the primary endpoint: a statistically significant reduction in annualized clinical fracture rate versus placebo or bisphosphonates.
Shares dropped sharply on the news, and the company…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.